media – Page 321 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Roche Partners with Alnylam on Hypertension Therapy in Deal Worth up to $2.8bn

Roche has entered into a new partnership with Alnylam Pharmaceuticals to develop and commercialise a potential treatment for high blood pressure, with the deal worth up to $2.8bn. The candidate, zilebesiran, is an investigational, subcutaneously administered RNAi therapeutic currently in phase 2 development to treat hypertension in populations with high-unmet needs. Under the terms of the agreement, which provides Roche with exclusive commercialisation rights to the therapy outside of the US and joint commercialisation rights within the country, Alnylam will receive an upfront payment of $310m and is also eligible to receive certain milestone payments. Hypertension, the leading cause of cardiovascular disease, affects more than 1.2 billion adults worldwide. While several therapies exist, a significant unmet need remains, especially for high-risk patients. Zilebesiran works by preventing the production of angiotensinogen, a protein that plays a key role in raising blood pressure, in the liver. ...
- Source: drugdu
- 233
- July 26, 2023
Sandoz Granted Positive CHMP Opinion for Multiple Sclerosis Biosimilar

Sandoz, a Novartis division, has announced that its multiple sclerosis (MS) biosimilar has been recommended by the European Medicines Agency’s (EMA) human medicines committee as a single disease-modifying therapy in adults with highly active relapsing-remitting forms of the disease. The “first-of-a-kind” biosimilar natalizumab, developed by Polpharma Biologics, is a version of Tysabri (natalizumab). Biosimilars, according to the EMA, are biological products that are highly similar to a medicine already approved in the EU. The drugs have no clinically significant differences in terms of safety or effectiveness from the reference product, but they could potentially lower healthcare costs. Pierre Bourdage, chief commercial officer, Sandoz, said: “Access to affordable, high-quality treatments like disease-modifying therapies – which are a cornerstone in the treatment of MS – remains limited for many people living with this disease.” Over 2.8 million people worldwide are affected by MS, a disabling and unpredictable ...
- Source: drugdu
- 123
- July 26, 2023
Quality of Snacking Matters More Than Quantity or Frequency, Study Shows

Snacking is becoming increasingly popular, with more than 70% of people reporting they snack at least twice a day. In a new study involving more than 1,000 people, researchers examined whether snacking affects health and if the quality of snack foods matters. Kate Bermingham (PhD, postdoctoral fellow, King’s College London) said, “Our study showed that the quality of snacking is more important than the quantity or frequency of snacking, thus choosing high quality snacks over highly processed snacks is likely beneficial. Timing is also important, with late night snacking being unfavorable for health.” Bermingham will present the findings at NUTRITION 2023, the annual flagship meeting of the American Society for Nutrition held July 22-25 in Boston. The work is part of the ZOE PREDICT project, a group of large in-depth nutritional research studies designed to uncover how and why people respond differently to the same foods. ...
- Source: drugdu
- 118
- July 26, 2023
Daily Prune Consumption Has Promising Effects on Biomarkers Related to Cardiovascular Health

A pair of new studies presented as abstracts today at the American Society of Nutrition (ASN) annual meeting report that daily prune consumption has promising effects on several biomarkers related to cardiovascular health. Conducted in postmenopausal women and men 55 years and older, the studies reveal: In men, long-term prune consumption improved HDL cholesterol and the total cholesterol to HDL ratio, while decreasing oxidative stress and the inflammatory biomarker C-reactive protein (CRP). In older women, long-term prune consumption had no negative effect on various metabolic measures related to heart disease risk including total cholesterol, total triglycerides, fasting glucose, and insulin levels. The results of both studies were presented at the ASN annual flagship meeting in Boston, MA. The ASN convenes researchers, practitioners, global and public health professionals, policymakers and advocacy leaders, industry, media, and other related professionals to advance nutrition science and its practical application. “Currently, there ...
- Source: drugdu
- 246
- July 26, 2023
Study Links Associative Learning in the Cerebellum to Movement Control in Mice

The cerebellum, a region at the back of the brain under the cerebral cortex, has been found to support movement and muscle control, as well as memory, learning and other mental functions. Some neuroscience studies have hypothesized that the cerebellum refines the movements of humans and other mammals via associative learning, yet this has yet to be established with certainty. Researchers at the University of Colorado School of Medicine recently carried out a study exploring this possibility by changing the activity of the mouse cerebellum and observing how this impacted overall neural activity and the mice’s reaching behavior. Their findings, published in Nature Neuroscience, offer new valuable insight about the involvement of the cerebellum in motor control. “The cerebellum is prized by those of us who study it as a tractable circuit—it is set apart from the rest of the brain yet linked to the rest of the brain through ...
- Source: drugdu
- 135
- July 26, 2023
Roche Expands Into RNAi Through Alnylam Alliance on Hypertension Drug

Photo: Giuseppe Aresu/Bloomberg, via Getty Images Alnylam pioneered RNA interference drugs for rare disease. The biotech aims to bring RNAI to prevalent disorders and its alliance with Roche on the drug zilebesiran for hypertension better positions the company to achieve this goal. Cardiometabolic disease isn’t a big part of Roche’s drug portfolio or pipeline, but the pharmaceutical giant is trying to change that with a deal to share in the development of an experimental Alnylam Pharmaceuticals hypertension drug that could offer patients efficacy and dosing advantages. According to deal terms announced Monday, Roche is paying $310 million for outside-of-the-U.S. rights to the drug, zilebesiran. The companies will share in the development of the RNA therapy for hypertension. Roche has the opportunity to lead future development of the drug for other indications. Cambridge, Massachusetts-based Alnylam is a pioneer among companies developing therapies that leverage RNA interference, a pathway in ...
- Source: drugdu
- 115
- July 26, 2023
Top 5 Foods with the Highest Prebiotic Content

There is growing evidence that consuming prebiotics -; certain types of fiber often found in plants that stimulate beneficial bacteria in your gut -; can help to maintain a healthy gut microbiome. In a new study, scientists estimated the prebiotic content of thousands of food types by using preexisting literature to find out which foods offer the highest prebiotic content. According to the study, foods that pack the greatest prebiotic punch are dandelion greens, Jerusalem artichokes, garlic, leeks, and onions. In addition to supporting gut microbes, prebiotic rich foods contain high amounts of fiber -; something most Americans do not get enough of. “Eating prebiotic dense foods has been indicated by previous research to benefit health,” said Cassandra Boyd, a master’s student at San José State University who conducted the research with Assistant Professor John Gieng, PhD. “Eating in a way to promote microbiome wellness while eating ...
- Source: drugdu
- 230
- July 25, 2023
Majority of Cosmetic Practitioners in the UK are not Qualified Medical Doctors, Study Finds

According to an analysis of the UK’s cosmetic injectables industry by UCL researchers, 68% of cosmetic practitioners who are administering injections such as Botox are not qualified medical doctors. The study, published in the Journal of Plastic, Reconstructive & Aesthetic Surgery, is the first survey of who is providing cosmetic injectable services, such as Botulinum Toxin (Botox) and Dermal Fillers, in the UK. Currently, little is known about the background qualifications, training and experience levels of those who are administering treatments. To fill this knowledge gap, researchers from UCL evaluated 3,000 websites to identify 1,224 independent clinics and 3,667 practitioners who were delivering cosmetic injections such as Botox. Of the professions represented, 32% were doctors, 13% were nurses, 24% were dentists and 8% were dental nurses. Of the 1,163 doctors identified, 41% were on the specialist register and 19% were on the GP register. Among the ...
- Source: drugdu
- 139
- July 25, 2023
ADC Discontinues Zynlonta Trial in DLBCL After Seven Deaths

Pictured: Doctor checking a patient’s neck/iStock, stefanamer ADC Therapeutics is discontinuing the Phase II LOTIS-9 trial testing Zynlonta (loncastuximab tesirine-lpyl) in combination with Genentech and Biogen’s Rituxan (rituximab) for patients with previously untreated diffuse large B-cell lymphoma, the company announced Thursday afternoon. The decision to discontinue comes after the Swiss biotech decided last week to voluntarily halt enrollment in LOTIS-9 after seven patients died of extreme respiratory events. While six of the fatalities were deemed “unlikely or unrelated to the study drug,” the company nevertheless elected to suspend the entry of patients into the study. In connection with the deaths, the FDA has also placed a partial clinical hold on enrollment into LOTIS-9, according to ADC’s Thursday press release. However, the company can continue dosing diffuse large B-cell lymphoma (DLBCL) patients who were seeing clinical benefit from the experimental treatment regimen, as long as these patients have given their consent again. Once ...
- Source: drugdu
- 243
- July 25, 2023
Vir’s GSK-Backed Flu Vaccine Candidate Fails Phase II Trial

Pictured: Flu vaccine vials and syringe/iStock, vchal Topline data from the Phase II PENINSULA study showed that Vir Biotechnology’s investigational flu shot VIR-2482 fell short of its primary and all secondary efficacy endpoints, the biotech announced Thursday. Patients inoculated with the highest 1,200-mg dose of the vaccine candidate saw a 16% drop in influenza A-like illness as compared with placebo, an effect that did not satisfy statistical significance, according to Vir’s news release. PENINSULA defined this primary endpoint as PCR-confirmed influenza A infection with at least one respiratory and one systemic symptom. Phil Pang, Vir’s chief medical officer, called these findings “disappointing” in a statement, but nevertheless said that the company needs to conduct further analysis to “better understand these outcomes.” Vir plans to present these analyses at a future major medical congress. PENINSULA is double-blinded, randomized and placebo-controlled study with approximately 3,000 adult patients enrolled. VIR-2482 was given as a ...
- Source: drugdu
- 153
- July 25, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.